Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Maria Sklodowska-Curie National Research Institute of Oncology

Home Clinical Trial Sponsors and OrganizationsMaria Sklodowska-Curie National Research Institute of Oncology

Maria Sklodowska-Curie National Research Institute of Oncology

ACTIVE

Polandwww.pib-nio.plPrivateEstablished: 1951-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

64

5 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1951

Overview

Trial Phase Distribution

Phase

Trials

Share

Not Applicable

24

37.5%

Phase 2

18

28.1%

Phase 3

8

12.5%

Phase 1

4

6.3%

Phase 4

2

3.1%

Trial Status Distribution

Active, not recruiting

4

6.3%

Completed

19

29.7%

Not yet recruiting

1

1.6%

Recruiting

16

25.0%

Unknown

23

35.9%

Withdrawn

1

1.6%

Clinical Trials

Trials sponsored by this organization (64)

Optimal Radiotherapy - Heel Spur Syndrome - Randomized Clinical Trial

Mar 2026366 participants

NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery

Aug 2025225 participants

Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy

Not yet recruiting

Jun 202560 participants

177Lu-PSMA As a Systemic Adjuvant Treatment in Patients with High and Very High Risk Prostate Cancer

Jan 2025200 participants

Stereotactic Radiosurgery in the Treatment of Essential Tremor

Dec 202442 participants

Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer

Apr 202478 participants

The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial

Jan 202432 participants

Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines

Active, not recruiting

Sep 2023220 participants

Page 1 of 8

Approvals

No approval data available

News

Nemtabrutinib Shows Promise in Relapsed/Refractory Follicular Lymphoma

- Nemtabrutinib demonstrates encouraging efficacy in patients with relapsed or refractory follicular lymphoma, according to findings from the BELLWAVE-003 phase 2 trial. - The study, presented at the 2024 ASH Annual Meeting, highlights the potential of nemtabrutinib as a treatment option for this patient population. - Safety data from the trial indicate a manageable toxicity profile, supporting the continued investigation of nemtabrutinib in follicular lymphoma. - Further research is warranted to confirm these findings and explore the optimal use of nemtabrutinib in the treatment landscape.

On this page

Overview
Clinical Trials64
Approvals
News1

Back to Organizations